This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria's on! PLUS Launch Fuels Oral Tobacco Profit Gains: What's Next?
by Zacks Equity Research
MO's Helix unit drives margin gains as new on! PLUS nicotine pouches launch in key states amid tough pricing pressure.
MO vs. PM: The Ultimate Face-Off in a Changing Tobacco Landscape
by Swati Prasad
Altria's pricing power, smoke-free gains and solid margins make it a standout against Philip Morris in a transforming tobacco market.
Should You Consider Buying Altria Stock Before Q3 Earnings Release?
by Vrishali Bagree
MO's Q3 results are likely to gain strength from pricing power, cost discipline and growing smoke-free momentum.
Philip Morris Q3 Earnings Beat Estimates, Revenues Increase 9% Y/Y
by Zacks Equity Research
PM posts a third-quarter earnings and revenue beat as its smoke-free business drives record profits and double-digit growth.
MO Optimize & Accelerate Initiative: Enough to Boost Long-Term EPS?
by Zacks Equity Research
Altria's Optimize & Accelerate program reinvests cost savings to fuel smoke-free growth and long-term EPS.
ETFs to Consider as Philip Morris Reports Q3 Earnings
by Yashwardhan Jain
Philip Morris beats Q3 estimates as smoke-free products surge, setting the stage for solid 2025 growth and higher EPS guidance.
Compared to Estimates, Philip Morris (PM) Q3 Earnings: A Look at Key Metrics (Revised)
by Zacks Equity Research
The headline numbers for Philip Morris (PM) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Philip Morris (PM) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Philip Morris (PM) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Philip Morris (PM) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of +6.67% and +1.32%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Philip Morris Stock in Q3 Earnings Release?
by Zacks Equity Research
PM is set for revenue and earnings growth in 3Q25, fueled by strong smoke-free momentum and solid global performance.
Philip Morris (PM) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Philip Morris (PM) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Altria Rises 12% in 3 Months: Should You Buy, Sell or Hold the Stock?
by Swati Prasad
MO's 12% 3-month surge highlights strong earnings, rising smoke-free sales and disciplined execution amid industry weakness.
Philip Morris (PM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Philip Morris (PM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria's Oral Margins Surge to 68.7%: Can the Strength Last?
by Zacks Equity Research
MO's oral segment OCI margin hits 68.7% as on! pouches boost profitability despite volume dips and rising competition.
Zacks Industry Outlook Highlights Philip Morris International, Altria and Turning Point Brands
by Zacks Equity Research
Despite declining cigarette sales, Philip Morris International, Altria, and Turning Point Brands are driving growth through smoke-free innovations and shifting consumer trends.
3 Tobacco Stocks to Keep an Eye on Amid Industry Challenges
by Swati Prasad
PM, MO and TPB are navigating declining cigarette sales and rising health awareness through smoke-free innovations and strategic portfolio expansion.
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
by Zacks Equity Research
SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
Top Stock Reports for SAP, Novartis & Philip Morris
by Mark Vickery
SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.
MO's on! Hits 8.7% Oral Tobacco Share: Can It Fend Off Competitors?
by Zacks Equity Research
Altria's on! nicotine pouch brand captures 8.7% of the U.S. oral tobacco market, fueling growth and brand momentum in a fierce competitive landscape.
Why Philip Morris (PM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MO vs. PM: Which Tobacco Giant is Better Positioned for the Future?
by Swati Prasad
Altria leans on pricing strength and nicotine pouch growth, while Philip Morris gains momentum with smoke-free products and global scale.
These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Philip Morris Raises Dividend: A Look at Its Growth Strategy
by Zacks Equity Research
PM has raised its quarterly dividend by 8.9%, underscoring growth through smoke-free products, cost savings and strong brands.
Altria Delivers 7.2% EPS Growth in 1H25 Despite Sales Headwinds
by Zacks Equity Research
MO's first half of 2025 EPS grows 7.2% to $2.67 despite revenue declines, as pricing, efficiency gains and buybacks lifted margins and returns.
Altria Stock Trading at a Discount: What's the Next Best Move?
by Swati Prasad
MO shows steady earnings and strong pricing power, though long-term momentum depends on balancing cigarette declines with smoke-free gains.